Aveo Oncology Inc. is getting $15 million up front in a potential $326 million deal with Novartis AG that hands over development and commercialization rights to preclinical-stage growth differentiation factor 15 (GDF15)-targeting antibody AV-380. Read More
Biolinerx Ltd., of Tel Aviv, Israel, initiated a phase IIb trial of BL-8040 as a consolidation treatment for acute myeloid leukemia (AML). The study will examine BL-8040 as part of a second stage treatment to improve outcomes for AML patients who achieved remission following induction therapy. Read More
Chiasma Inc., of Newton, Mass., reported that the FDA has accepted its new drug application for oral octreotide, a drug proposed for the maintenance therapy of adult patients with acromegaly. Read More
BOGOTA, Colombia – Most Latin American countries are developing new regulations and guidelines in an effort to facilitate the use of novel drugs and biosimilars in their health care systems. Bolivia, with a political regime in transition, stands as an exception in the region. Read More
Genentech Inc.'s most advanced immunotherapy candidate, atezolizumab, met its primary endpoint in a pivotal phase II study, shrinking tumors in people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose disease expressed programmed cell death ligand-1 (PD-L1), and setting the stage for an early 2016 registration filing. Read More
SHANGHAI – Acting on an offer first announced in April, Shanghai-based Wuxi Pharmatech Inc.'s board of directors has accepted a $3.3 billion privatization bid, effectively taking China's largest CRO off the NYSE. Read More
HONG KONG — The discovery that a novel mechanism of CD4+ T helper (Th) cell differentiation is mediated by co-stimulation of glucocorticoid-induced tumor necrosis factor receptor- (TNFR)-related protein (GITR) explains the mechanism of action of GITR-mediated cancer immunotherapies and warrants clinical trials of GITR agonists, a Korean study has found. Read More
LONDON – Summit Therapeutics plc finally has cracked the problem of delivering SMT C1100, a universal treatment for Duchenne muscular dystrophy (DMD), opening the way for phase II development to start later this year. Read More
Edge Therapeutics Inc., of Berkeley Heights, N.J., filed an S-1 statement with the SEC seeking to raise up to $115 million, including overallotments, in an IPO. Read More
